Aim of the work~To determine the benefits of statin use in CHC patients treated with Sofosbuvir/Daclatasvir/Ribavirin through :~Primary Outcome: Assessment of therapeutic SVR12~Seconadry Outcome~1. assessment of Chronic hepatitis C(CHC) infection risk on development of metabolic syndrome through assessment of lipid profile , fasting glucose test , HgbA1C and C-reactive protein(CRP).~2- Evaluation of CHC related complications such as fibrosis and cirrhosis~Patients will be followed up for the whole study period and will be subjected to assessment of the following:~CBC , liver function test , lipid profile and CK every month till the end of therapy.~HgA1C and CRP at the end of therapy.~HCV-PCR test 3 months after the end of therapy.~Fibrosis using (FIB-4) 3 months after the end of therapy.
The purpose of the study is to determine if statin can affect the clinical outcome of chronic hepatitis C patients receiving Sofosbuvir/Daclatasvir/Ribavirin combination